|
Synonyms: REGN-1033 | REGN1033 | SAR-391786 | SAR391786
Compound class:
Antibody
Comment: Trevogrumab is a fully human moncolonal antibody, being investigated for its potential to treat diseases/disorders which are ameliorated or improved by inhibition of myostatin (a.k.a. GDF8).
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. BLAST peptide searches of patented peptide sequences reveals exact matches between the heavy chain variable region (HCVR) and the light chain variable region (LCVR) of trevogrumab with sequences 360 and 368 respectively, from patent US8840894 B2 [3]. |
| References |
|
1. Latres E, Pangilinan J, Miloscio L, Bauerlein R, Na E, Potocky TB, Huang Y, Eckersdorff M, Rafique A, Mastaitis J et al.. (2015)
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle, 5: 34. [PMID:26457176] |
|
2. Ma JD, Heavey SF, Revta C, Roeland EJ. (2014)
Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther, 14 (8): 1113-20. [PMID:24707881] |
|
3. Stitt T, Latres E. (2014)
Antibodies to human GDF8. Patent number: US8840894 B2. Assignee: Regeneron Pharmaceuticals, Inc.. Priority date: 26/05/2010. Publication date: 23/09/2014. |
